-$0.37 Earnings Per Share Expected for Evofem Biosciences Inc (EVFM) This Quarter

Equities research analysts expect Evofem Biosciences Inc (NASDAQ:EVFM) to report ($0.37) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Evofem Biosciences’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.42). Evofem Biosciences reported earnings per share of ($0.78) during the same quarter last year, which suggests a positive year over year growth rate of 52.6%. The business is scheduled to issue its next quarterly earnings results before the market opens on Wednesday, November 7th.

According to Zacks, analysts expect that Evofem Biosciences will report full year earnings of ($5.32) per share for the current financial year, with EPS estimates ranging from ($6.43) to ($4.88). For the next year, analysts expect that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.53) to ($1.20). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Evofem Biosciences.

Evofem Biosciences (NASDAQ:EVFM) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.59).

Several analysts have issued reports on the company. ValuEngine upgraded Evofem Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday. Cantor Fitzgerald set a $9.00 price target on Evofem Biosciences and gave the stock a “buy” rating in a research note on Tuesday, October 30th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Evofem Biosciences in a research note on Wednesday, August 29th. Finally, Oppenheimer set a $9.00 price target on Evofem Biosciences and gave the stock a “buy” rating in a research note on Friday, August 3rd. Six analysts have rated the stock with a buy rating, Evofem Biosciences has an average rating of “Buy” and a consensus target price of $10.40.

In other news, Director Thomas G. Lynch purchased 100,000 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were purchased at an average cost of $2.26 per share, for a total transaction of $226,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders bought 121,715 shares of company stock worth $272,226. Company insiders own 3.40% of the company’s stock.

A hedge fund recently raised its stake in Evofem Biosciences stock. Millennium Management LLC increased its stake in Evofem Biosciences Inc (NASDAQ:EVFM) by 6,497.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 733,765 shares of the biotechnology company’s stock after purchasing an additional 722,643 shares during the quarter. Millennium Management LLC owned approximately 2.84% of Evofem Biosciences worth $1,989,000 at the end of the most recent quarter. 79.29% of the stock is currently owned by institutional investors.

Shares of EVFM remained flat at $$3.90 during mid-day trading on Wednesday. The company’s stock had a trading volume of 20,406 shares, compared to its average volume of 36,736. Evofem Biosciences has a 52-week low of $1.79 and a 52-week high of $12.90.

About Evofem Biosciences

Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.

See Also: What are Institutional Investors?

Get a free copy of the Zacks research report on Evofem Biosciences (EVFM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply